Brad S. Kahl

27.3k citations
385 papers · 11.3k indexed · 5 hit papers · h-index 49
Topics
Lymphoma Diagnosis and Treatment (325 papers)Chronic Lymphocytic Leukemia Research (180 papers)Viral-associated cancers and disorders (72 papers)
Journals
New England Journal of MedicineJournal of Clinical OncologySHILAP Revista de lepidopterología

In The Last Decade

Brad S. Kahl

370 papers receiving 11.1k citations

Hit Papers

Targeting BCL2 with Venetoclax in Relapsed Chro...2006202620122019201520062014201420214008001.2k

Peers

Brad S. Kahl
Comparison fields: 5 of 116
  • Pathology and Forensic Medicine 7.8k
  • Oncology 5.6k
  • Genetics 5.1k
  • Molecular Biology 2.4k
  • Immunology 1.8k
Replace Francesc Bosch with:
Francesc Bosch Spain
Myron S. Czuczman United States
Franck Morschhauser France
Laurie H. Sehn Canada
Bruce D. Cheson United States
Morton Coleman United States
Sonali M. Smith United States
Kristie A. Blum United States
Vincent Ribrag France
Steven Le Gouill France
Brad S. Kahl relative to Francesc Bosch Spain Francesc Bosch's profile →
Citations per field
00.5×3.5×
Francesc Bosch · 1×
Citations per year

Countries citing papers authored by Brad S. Kahl

Since Specialization
Citations

This map shows the geographic impact of Brad S. Kahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad S. Kahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad S. Kahl more than expected).

Fields of papers citing papers by Brad S. Kahl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad S. Kahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad S. Kahl. The network helps show where Brad S. Kahl may publish in the future.

Co-authorship network of co-authors of Brad S. Kahl

This figure shows the co-authorship network connecting the top 25 collaborators of Brad S. Kahl. A scholar is included among the top collaborators of Brad S. Kahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad S. Kahl. Brad S. Kahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 0
3 6
4 1
5 3
6 6
7 1
8 3
9 16
10 122
11 16
12 15
13 145
14 183
15 91
16 138
17
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studybreakdown →
419
18 55
19 194
20 118

About Brad S. Kahl

Brad S. Kahl is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 385 papers that have together received 11.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (325 papers), Chronic Lymphocytic Leukemia Research (180 papers) and Viral-associated cancers and disorders (72 papers). The work is most often cited by research in Genetics (5.1k citations), Pathology and Forensic Medicine (7.8k citations) and Oncology (5.6k citations). Brad S. Kahl has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Ian W. Flinn, Jennifer R. Brown, John P. Leonard, Richard I. Fisher, Randy D. Gascoyne, Ranjana H. Advani, Fangxin Hong, Nancy L. Bartlett, Bruce D. Cheson and David T. Yang. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026